These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 31096221)

  • 1. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
    Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis.
    Enomoto T; Aoki M; Hamasaki M; Abe H; Nonaka M; Inoue T; Nabeshima K
    Neurol Med Chir (Tokyo); 2020 Mar; 60(3):136-146. PubMed ID: 31902873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of H3K27M mutation, histone H3K27 methylation status, and EZH2 expression in diffuse spinal cord gliomas.
    Ishi Y; Takamiya S; Seki T; Yamazaki K; Hida K; Hatanaka KC; Ishida Y; Oda Y; Tanaka S; Yamaguchi S
    Brain Tumor Pathol; 2020 Jul; 37(3):81-88. PubMed ID: 32529280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 6. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
    Agarwal P; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.
    Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B
    Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
    Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
    Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
    Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
    Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis.
    Dhar S; Gadd S; Patel P; Vaynshteyn J; Raju GP; Hashizume R; Brat DJ; Becher OJ
    Acta Neuropathol Commun; 2022 Apr; 10(1):47. PubMed ID: 35395831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma.
    Lee CH; Yu JR; Granat J; Saldaña-Meyer R; Andrade J; LeRoy G; Jin Y; Lund P; Stafford JM; Garcia BA; Ueberheide B; Reinberg D
    Genes Dev; 2019 Oct; 33(19-20):1428-1440. PubMed ID: 31488577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.
    Justin N; Zhang Y; Tarricone C; Martin SR; Chen S; Underwood E; De Marco V; Haire LF; Walker PA; Reinberg D; Wilson JR; Gamblin SJ
    Nat Commun; 2016 Apr; 7():11316. PubMed ID: 27121947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
    La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
    World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
    Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V
    Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
    Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients.
    Wu Z; Wang Q; Wang L; Li G; Liu H; Fan F; Li Z; Li Y; Tu Y
    J Neurol Sci; 2013 Dec; 335(1-2):191-6. PubMed ID: 24139839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.
    Chai RC; Zhang YW; Liu YQ; Chang YZ; Pang B; Jiang T; Jia WQ; Wang YZ
    Acta Neuropathol Commun; 2020 Mar; 8(1):40. PubMed ID: 32228694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
    Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
    Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.
    Venneti S; Garimella MT; Sullivan LM; Martinez D; Huse JT; Heguy A; Santi M; Thompson CB; Judkins AR
    Brain Pathol; 2013 Sep; 23(5):558-64. PubMed ID: 23414300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas.
    Bechet D; Gielen GG; Korshunov A; Pfister SM; Rousso C; Faury D; Fiset PO; Benlimane N; Lewis PW; Lu C; David Allis C; Kieran MW; Ligon KL; Pietsch T; Ellezam B; Albrecht S; Jabado N
    Acta Neuropathol; 2014 Nov; 128(5):733-41. PubMed ID: 25200321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.